Short-term intravenous zoledronic acid in severe osteogenesis imperfecta : A report of three siblings of children
DOI:
https://doi.org/10.13181/mji.v17i2.310Keywords:
zoledronic acid, osteogenesis imperfecta, side effectsAbstract
This report documented the clinical and biochemical side effects on the first dose of intravenous zoledronic acid therapy in three siblings with severe osteogenesis imperfecta. Zoledronic acid was administered in 50 ml 0.9% saline solution over a period of 30 minutes. All patients had fever during the first 6 to 48 hours after the first infusion. There were no renal side effects, apart from asymptomatic hypocalcemia and hypophosphatemia at 48 and 72 hours after zoledronic acid infusion. The minimal clinical side effects were easily manageable. (Med J Indones 2008; 17: 127-30)
Downloads
Download data is not yet available.
Downloads
Published
2008-05-01
How to Cite
1.
Lim H, Zein U, Siregar Y, Marpaung B, Sinaga J. Short-term intravenous zoledronic acid in severe osteogenesis imperfecta : A report of three siblings of children. Med J Indones [Internet]. 2008May1 [cited 2024Nov.27];17(2):127-30. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/310
Issue
Section
Clinical Research
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
